von Tobias Borgers | Aug 16, 2021 | Boehringer
Introduction Chronic obstructive pulmonary disease (COPD) is a preventable and modifiable condition characterized by irreversible or poorly reversible airflow obstruction and persistent respiratory symptoms due to airway and/or alveolar abnormalities. The disease is...
von Tobias Borgers | Aug 10, 2021 | Boehringer
HELSINKI, Aug. 3, 2021 /PRNewswire/ — Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform’s award-winning CESS® technology...
von Tobias Borgers | Aug 10, 2021 | Bayer
Berlin, 5. August 2021 – Die Bayer AG hat Vividion Therapeutics, Inc. (Vividion), ein biopharmazeutisches Unternehmen mit Hauptsitz in den USA, das durch neue Forschungstechnologien einen hohen Mehrwert erzielt, erworben. So kann Vividion traditionell nicht...
von Tobias Borgers | Aug 3, 2021 | Boehringer
Wissenschaftlerin im Labor Innovative Zelltherapien gelten als Hoffnungsträger in der Krebsmedizin. Frankfurt Das Berliner Biotech-Unternehmen T-Knife hat seine nächste große Finanzierungsrunde abgeschlossen. Insgesamt 110 Millionen Dollar konnte das 2018 gegründete...
von Tobias Borgers | Jul 31, 2021 | Boehringer
RHEA Generics, a homegrown pioneer in the marketing and distribution of high-quality and affordable health-care products, has entered a new partnership with leading pharmaceutical company Boehringer Ingelheim (Philippines) Inc. The initial offering from this...
von Tobias Borgers | Jul 31, 2021 | Bayer
Enko, a crop health company, has announced details on its partnership with Bayer to develop diverse chemistries for crop protection. Applying drug discovery approaches from pharma to crop protection will allow the companies to identify unexpected product candidates...
